Cancer treatment: an update
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Paris u.a.
Springer
1994
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Item Description: | Literaturangaben |
| Physical Description: | XIX, 901 S. Ill., graph. Darst. |
| ISBN: | 2287003924 3540595996 0387595996 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV009261274 | ||
| 003 | DE-604 | ||
| 005 | 19940519 | ||
| 007 | t | ||
| 008 | 940324s1994 ad|| |||| 10||| engod | ||
| 016 | 7 | |a 940873346 |2 DE-101 | |
| 020 | |a 2287003924 |9 2-287-00392-4 | ||
| 020 | |a 3540595996 |9 3-540-59599-6 | ||
| 020 | |a 0387595996 |9 0-387-59599-6 | ||
| 035 | |a (OCoLC)31015396 | ||
| 035 | |a (DE-599)BVBBV009261274 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 | ||
| 082 | 0 | |a 616.994 | |
| 084 | |a XH 3105 |0 (DE-625)152887:12911 |2 rvk | ||
| 245 | 1 | 0 | |a Cancer treatment |b an update |c ed. by : P. Banzet ... |
| 264 | 1 | |a Paris u.a. |b Springer |c 1994 | |
| 300 | |a XIX, 901 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben | ||
| 650 | 4 | |a Combined Modality Therapy |v Congresses | |
| 650 | 4 | |a Neoplasms |x drug therapy |v Congresses | |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1993 |z Paris |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Banzet, Pierre |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006162977&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-006162977 | |
Record in the Search Index
| _version_ | 1807502942555602944 |
|---|---|
| adam_text |
CONTENTS
FOREWORD
.
XXI
EDUCATIONAL
LECTURES
THE
PATHOGENESIS
OF
HUMAN
CANCER
METASTASIS,
I.J.
FIDLER
.
3
THE
ROLE
OF
MOLECULAR
GENETICS
IN
MEDICAL
ONCOLOGY,
E.J.
FREIREICH
.
7
CELL
LINE-BASED
SCREENING
FOR
NEW
ANTICANCER
DRUGS,
B.A.
CHABNER,
J.N.
WEINSTEIN,
K.D.
PAULL,
M.R.
GREVER
.
10
ANTI-EGF
RECEPTOR
MONOCLONAL
ANTIBODIES
AS
POTENTIAL
ANTI-CANCER
THERA
PY,
J.
MENDELSOHN
.
17
CLINICAL
RELEVANCE
OF
DRUG
RESISTANCE
:
WHERE
DO
WE
STAND
NOW
AND
WHERE
ARE
WE
GOING
TO
?,
S.C.
LINN,
G.
GIACCONE,
H.M.
PINEDO
.
19
MOBILIZATION,
PURIFICATION
AND
EX
VIVO
EXPANSION
OF
HUMAN
PERIPHERAL
BLOOD
PROGENITOR
CELLS,
W.
BRUGGER,
R.
MERTELSMANN,
L.
KANZ
.
24
FLUOROPYRIMIDINE
CANCER
CHRONOTHERAPY,
W.J.M.
HRUSHESKY,
F.O.
COPE
29
CHEMO-IMMUNOTHERAPY
OF
METASTATIC
MALIGNANT
MELANOMA.
THE
SAL
PETRIERE
HOSPITAL
(SOMPS)
EXPERIENCE,
D.
KHAYAT,
E.
ANTOINE,
O.
RIXE,
J.M.
TOURANI,
E.
VUILLEMIN,
CH.
BOREL,
A.
BENHAMMOUDA,
L.
THILL,
C.
FRANKS,
G.
AUCLERC,
M.
WEIL,
CL.
SOUBRANE,
P.
BANZET
.
40
CONCOMITANT
CHEMORADIOTHERAPY
FOR
SOLID
TUMORS,
E.E.
VOKES,
R.
STUPP
47
CURRENT
STATUS
OF
THERAPY
FOR
SMALL
CELL
CARCINOMA
OF
THE
LUNG,
D.C.
IHDE
.
50
SYSTEMIC
TREATMENT
OF
BLADDER
CANCER,
L.Y.
DIRIX,
A.T.
VAN
OOSTEROM
55
METASTATIC
BREAST
CANCER
:
CURRENT
MANAGEMENT
OPTIONS
AND
FUTURE
DIREC
TIONS,
G.
HORTOBAGYI
.
62
PRESENT
AND
FUTURE
PROSPECTS
FOR
THE
CHEMOTHERAPY
OF
GLIOMAS,
V.
LEVIN
66
NEO-ADJUVANT
CHEMOTHERAPY
IN
BREAST
CANCER.
STUDY
OF
477
EVALUABLE
PA
TIENTS
WITH
PRIMARY
BREAST
CANCERS
TREATED
BETWEEN
1980
AND
1992,
M.
WEIL,
G.
AUCLERC,
CH.
BOREL,
F.
BAILLET,
A.
THOMAS,
CL.
SOUBRANE,
M.
HOUSSET,
D.
NIZRI,
O.
RIXE,
E.
ANTOINE,
E.
VUILLEMIN,
D.
KHAYAT
70
OSTEOGENIC
SARCOMA
:
A
15-YEAR
EXPERIENCE
IN
TREATING
287
PATIENTS
WITH
PREOPERATIVE
CHEMOTHERAPY,
G.
ROSEN,
S.
LOWENBRAUN,
C.
FORSCHER
.
79
CELL
CYCLE
REGULATION
AND
THE
CHEMOSENSITIVITY
OF
CANCER
CELLS,
K.W.
KOHN,
P.M.
O
'
CONNOR
.
85
REVERSAL
OF
MULTIDRUG
RESISTANCE
OF
HEMATOLOGIC
MALIGNANCIES
WITH
CHEMOSENSITIZERS
:
LABORATORY
AND
CLINICAL
STUDIES,
S.E.
SALMON,
T.P.
MILLER,
A.F.
LIST,
T.M.
GROGAN,
W.S.
DALTON
.
90
PRACTICAL
APPROACH
TO
BLADDER
CANCER,
L.
DENIS
.
98
VI
CONTENTS
BREAST
CANCER
PRIMARY
CHEMOTHERAPY
FOR
BREAST
CANCER
:
RESPONSE
TO
PREOPERATIVE
CHEMOTHERAPY
AS
PROGNOSTIC
FACTOR,
G.N.
HORTOBAGYI,
A.U.
BUZDAR,
D.
FRYE,
S.E.
SINGLETARY,
F.A.
HOLMES,
F.
AMES,
M.D.
MCNEESE,
R.L.
THERIAULT
.
105
BREAST
CANCER,
CYTOPROGNOSTIC
GRADES
AND
PROLIFERATIVE
ACTIVITY
(DNA
PLOIDY,
S
PHASE)
MA
DE
MAUBLANC
.
110
PRIMARY
CHEMOTHERAPY
IN
THE
INDIVIDUALIZED
NON-MUTILATING
TREATMENT
OF
BREAST
CANCER,
R.
POISSON,
S.
LEGAULT,
R.
GUEVIN
.
114
NEO-ADJUVANT
CHEMOTHERAPY
IN
100
PATIENTS
WITH
LOCALLY
ADVANCED
CARCI
NOMA
OF
THE
BREAST,
B.
COUDERT,
P.
GABEZ,
C.
LAMAILLE,
C.
DE
GISLAIN,
F.
MAYER,
P.
FARGEOT
.
120
SURGICAL
ASPECTS
OF
THE
CONSERVATIVE
TREATMENT
OF
LARGE
SIZE
BREAST
CANCER
AFTER
PRIMARY
CHEMOTHERAPY,
S.
ZURRIDA,
M.
GRECO,
V.
GALIMBERTI,
U.
VERONESI
.
123
EFFICACY
OF
A
CHEMOTHERAPY
REGIMEN
COMBINING
VINORELBINE,
EPIRUBICINE
AND
METHOTREXATE
(VEM)
IN
LOCALLY
ADVANCED
AND
METASTATIC
BREAST
CANCER,
J.
VAN
PRAAGH,
N.
MARTINEAU,
V.
FEILLEL,
H.
CURE,
E.
BELEMBAOGO,
M.A.
RAVOUX,
J.
FLEURY,
C.
DELOCHE,
R.
PLAGNE,
P.
CHOLLET
.
127
RECURRENT
BREAST
CARCINOMA
AFTER
CONSERVATIVE
TREATMENT
:
MRI
FEATURES
AND
PATHOLOGIC
CORRELATION,
T.-H.
DAO,
F.
CAMPANA,
A.
FOURQUET,
M.
LAURENT,
B.
ASSELAIN,
A.
RAHMOUNI
.
131
INTENSIVE
CHEMOTHERAPY
FOR
INFLAMMATORY
BREAST
CANCER
:
HOW
MUCH
CLIN
ICAL
VALUE
?,
B.
CHEVALLIER,
C.
COUTEAU,
D.
ATLAN,
V.
CHATIKHINE,
Y.
GRAIC,
J.-P.
JULIEN,
A.
KUNLIN,
P.
BASTIT,
C.
VEYRET,
J.
D
'
ANJOU
.
135
A
PHASE
II
STUDY
OF
2-WEEKLY
HIGH-DOSE
EPIRUBICIN
WITH
R-MET-HU
G-CSF
IN
ADVANCED
BREAST
CANCER,
G.
FOUNTZILAS,
D.
SKARLOS,
T.
GIANNAKAKIS,
A.
ATHANASIADES,
D.
BAFALOUKOS,
J.
PROTOPSALTIS,
M.
BEER,
N.
PAVLIDIS,
P.
KOSMIDIS
.
146
CYCLOPHOSPHAMIDE,
NOVANTRONE,
FLUOROURACIL
(CNF)
+
G-CSF
NEO
ADJUVANT
CHEMOTHERAPY
IN
OPERABLE
BREAST
CANCER,
V.
LORUSSO,
M.
DE
LENA,
M.
BRANDI,
S.
LONGO,
F.
BERARDI,
A.
CATINO,
M.G.
SAPIA,
G.
SI
MONE,
F.
MARZULLO,
A.
RACANELLI,
F.
SCHITTULLI
.
150
ADJUVANT
CHEMOHORMONAL
THERAPY
WITH
CYCLOPHOSPHAMIDE,
DOXORUBICIN
AND
5-FLUOROURACII
(CAF)
WITH
OR
WITHOUT
MEDROXYPROGESTERONE
ACETATE
(MPA)
IN
NODE-POSITIVE
BREAST
CANCER
PATIENTS,
P.
HUPPERETS,
J.
WILS,
L.
VOLOVICS,
L.
SCHOUTEN,
M.
FICKERS,
H.
BRON,
H.
SCHOUTEN,
J.
JAGER,
J.
SMEETS,
J.
DE
JONG,
G.
BLIJHAM
.
155
FOLLOW-UP
RESULTS
OF
AN
ECOG
STUDY
OF
ADJUVANT
THERAPY
IN
POST
MENOPAUSAL
WOMEN
WITH
BREAST
CANCER,
H.C.
FALKSON,
R.
GRAY,
W.H.
WOLBERG,
G.
FALKSON
.
160
LONG-TERM
EFFICACY
AND
LATE
SEQUELAE
OF
DOXORUBICIN-CONTAINING
ADJUVANT
THERAPY
FOR
BREAST
CANCER
:
MD
ANDERSON
CANCER
CENTER
STUDIES,
A.
BUZ
CONTENTS
VII
DAR,
G.
HORTOBAGYI,
S.
KAU,
F.
HOLMES,
G.
FRASCHINI,
R.
THERIAULT,
M.
MCNEESE,
S.
SINGLETARY
.
163
TAXOL
IN
METASTATIC
BREAST
CANCER
:
THE
MD
ANDERSON
CANCER
CENTER
EX
PERIENCE,
F.A.
HOLMES,
V.
VALERO,
R.
WALTERS,
R.
THERIAULT,
D.
BOOSER,
A.
BUZDAR,
H.
GIBBS,
D.
FRYE,
K.
YOUNG,
G.
HORTOBAGYI
.
167
TAXOL
PLUS
RECOMBINANT
HUMAN
GRANULOCYTE
COLONY
STIMULATING
FACTOR
AS
SALVAGE
CHEMOTHERAPY
FOR
METASTATIC
BREAST
CANCER,
A.D.
SEIDMAN,
B.S.
REICHMAN,
J.P.A
CROWN,
T.-J.
YAO,
V.
CURRIE,
T.B.
HAKES,
C.A.
HU
DIS,
T.A.
GILEWSKI,
P.
FORSYTHE,
J.
LEPORE,
L.
MARKS,
M.
SOUHRADA,
N.
ONETTO,
S.
ARBUCK,
L.
NORTON
.
172
HEAD
AND
NECK
CANCER
A
MODEL
FOR
CHEMOSENTIVITY
TESTING
USING
IN
VITRO
MTT
ASSAY
ON
A
HU
MAN
SQUAMOUS
CARCINOMA
TONGUE
CELL
LINE,
W.K.
WALTER
KING,
P.K.
LAM,
K.C.
ARTHUR
LI
.
179
HEAD
AND
NECK
CANCER
TREATMENT
:
PRESENT
STATUS
AND
FUTURE
DIRECTION,
M.
AL-SARRAF
.
185
CHEMOTHERAPY
(CT)
FOLLOWED
BY
RADIOTHERAPY
(RT)
VS.
RT
ALONE
IN
PA
TIENTS
WITH
RESECTED
AND
NEGATIVE
MARGINS
SQUAMOUS
CELL
CARNINOMA
OF
THE
HEAD
AND
NECK
:
PHASE
III
INTERGROUP
STUDY,
M.
AL-SARRAF,
C.B.
SCOTT,
K.
AHMAD,
J.G.
SCHWADE,
D.
SCHULLER,
G.E.
LARAMORE,
J.
JACOBS
191
NEO-ADJUVANT
INFUSION
CISPLATIN,
5-FU
AND
HIGH-DOSE
LEUCOVORIN
FOR
SQUA
MOUS
CELL
CARCINOMA
OF
THE
HEAD
AND
NECK
(SCCHN)
:
HIGH
RATES
OF
COM
PLETE
RESPONSE
(CR)
AND
DEFINITIVE
RADIOTHERAPY
AS
PRIMARY
SITE
MANAGE
MENT,
J.
CLARK,
A.
DREYFUSS,
P.
BUSSE,
C.
NORRIS
JR,
J.
LUCARINI,
R.
ROS
SI,
J.
ANDERSEN,
D.
CASEY,
E.
FREI
III
.
196
PRIMARY
(NEO-ADJUVANT)
COMBINED
MODALITY
THERAPY
IN
THE
MANAGEMENT
OF
LOCALLY
ADVANCED
SQUAMOUS
CELL
CARCINOMA
OF
THE
HEAD
AND
NECK,
G.
MANTOVANI,
E.
PROTO,
L.
CONTINI,
S.
LITTERA,
L.
CURRELI,
F.
COSSU,
P.
PUXEDDU,
G.S.
DEL
GIACCO
.
201
A
PHASE
II
TRIAL
OF
INDUCTION
CISPLATIN,
5-FU,
LEUCOVORIN
AND
INTERFERON
A-2B
(PFL-A)
FOLLOWED
BY
CONCURRENT
HYDROXYUREA,
5-FU
AND
RADIATION
FOR
STAGE
IV
SQUAMOUS
CELL
CANCERS
OF
THE
HEAD
AND
NECK
(HNC),
M.S.
KIES,
D.J.
HARAF,
B.
MITTAL,
I.
ATHANASIADIS,
M.
KOZLOFF,
J.
MCEVIL
LY,
R.
MICK,
W.
MORAN,
W.
PANJE,
H.
PELZER,
T.D.
SHEEHAN,
R.
WEICH
SELBAUM,
B.
WENIG,
E.E.
VOKES
.
207
INDUCTION
CHEMOTHERAPY
WITH
CISPLATIN
(P),
5-FLUOROURACIL
(FU)
AND
FO
LINIC
ACID
(FA)
IN
LOCALLY
ADVANCED
HEAD
AND
NECK
CANCER,
E.
FONSECA,
J.-J.
CRUZ,
J.
GARCIA,
A.
PANADERO,
P.
SANCHEZ,
A.
GOMEZ,
G.
MARTIN,
M.-J.
GARCIA,
J.-C.
VALLEJO
.
211
A
RANDOMIZED
STUDY
OF
CDDP
AND
5-FU
AS
NEO-ADJUVANT
CHEMOTHERA
PY
IN
HEAD
AND
NECK
CANCER
:
AN
INTERIM
ANALYSIS,
M.
MARTIN,
L.
VERGNES,
LELIEVRE,
P.
MICHEL-LANGLET,
C.
PEYTRAL,
J.-J.
MAZERON,
E.
MALAURIE,
R.
PEYNEGRE
.
214
VIII
CONTENTS
CONCOMITANT
CHEMORADIOTHERAPY
IN
LOCALLY
ADVANCED
HEAD
AND
NECK
CANCERS
:
A
PROSPECTIVE
STUDY
OF
68
PATIENTS,
S.
WALTER,
C.
HENNEQUIN,
M.D.
BRETTE,
P.
LEBLANC,
P.Y.
CHERIFF-CHEIKH,
M.
ESPIE,
J.-P.
MON
TEIL,
M.
MARTY,
C.
MAYLIN
.
219
EPIDERMAL
GROWTH
FACTOR
RECEPTOR
IN
UPPER
AERODIGESTIVE
TRACT
CANCER,
J.-L.
FORMENTO,
M.
FRANCOUAL,
O.
DASSONVILLE,
J.
SANTINI,
A.
RAMAIOLI,
G.
MILANO,
M.
SCHNEIDER,
F.
DEMARD
.
225
CONCOMITANT
A-INTERFERON
AND
CHEMOTHERAPY
IN
ADVANCED
SQUAMOUS
CELL
CARCINOMA
OF
THE
HEAD
AND
NECK,
M.
BENASSO,
M.
MERLANO,
F.
BLENGIO,
M.
CAVALLARI,
R.
ROSSO,
S.
TOMA
.
234
THYMIDYLATE
SYNTHASE
ACTIVITY
AND
FOLATE
LEVELS
IN
HEAD
AND
NECK
SQUA
MOUS
CELL
CARCINOMAS,
O.
PARISE
JR,
F.
JANOT,
B.
LUBOINSKI,
M.-A.
VER
JUS,
A.
GOUYETTE,
G.-G.
CABOT
.
237
LONG
TERM
NEPHROTOXICITY
OF
CISPLATINUM
(CDDP)
IN
MAN,
Y.
BAHMED,
M.
DECHAUX,
V.
BASSOT,
D.
BRASNU,
C.
KINDERMANS,
H.
LACCOURREYE,
C.
SACHS
.
243
PROGNOSTIC
FACTORS
IN
HEAD
AND
NECK
CANCER
PATIENTS
INCLUDED
IN
A
PRO
GRAM
OF
NEO-ADJUVANT
CHEMOTHERAPY
AND
RADICAL
RADIOTHERAPY,
J.
CASTIL
LO,
F.
GOMEZ,
R.
GUERRERO,
P.
SANCHEZ,
I.
MARTIN
LOPEZ,
J.
CUETO,
J.-L.
GARCIA
PUCHE
.
248
INDUCTION
CHEMOTHERAPY
FOR
LARYNX
PRESERVATION
IN
LARYNGEAL
AND
HYPOPHARYNGEAL
CANCERS,
F.
DEMARD,
M.
SCHNEIDER,
O.
DASSONVILLE,
P.
CHAUVEL,
A.
THYSS,
J.
SANTINI
.
251
A
PILOT
STUDY
OF
VINORELBINE
ON
A
WEEKLY
SCHEDULE
IN
RECURRENT
AND/OR
METASTATIC
SQUAMOUS
CELL
CARCINOMA
OF
THE
HEAD
AND
NECK,
V.
GEBBIA,
A.
TESTA,
R.
VALENZA,
G.
ZERILLO,
S.
RESTIVO,
F.
INGRIA,
G.
CANNATA,
N.
BORSELLINO,
N.
GEBBIA
.
257
CONCOMITANT
RADIOTHERAPY
AND
CISPLATIN
IN
HEAD
AND
NECK
CANCER
:
A
PI
LOT
STUDY,
P.
OLMI,
C.
FALLAI,
C.
CHIOSTRINI
.
260
IFOSFAMIDE/MESNA
PLUS
CARBOPLATIN
AS
NEO-ADJUVANT
THERAPY
FOR
STAGE
I-III
HEAD
AND
NECK
CANCER.
PRELIMINARY
REPORT,
M.
BRUNO
.
263
ROLE
OF
IFOSFAMIDE,
CISPLATINUM
(IC)
COMBINATION
IN
THE
METASTATIC
NECK
NODES,
V.-R.
PAI,
D.-M.
PARIKH,
A.T.
MAZUMDAR,
R.S.
RAO
.
267
CLINICAL
PHARMACOKINETICS
OF
PURE
1
FOLINIC
ACID
AND
FLUOROURACIL
DUR
ING
A
PHASE
I-II
TRIAL
OF
FLUOROURACIL
BIOMODULATION
IN
HEAD
AND
NECK
CANCER
PATIENTS.
PRELIMINARY
DATA,
M.C.
ETIENNE,
G.
MILANO,
M.
SCHNEIDER,
A.
THYSS,
O.
DASSONVILLE,
M.
BARDON,
T.
GUILLOT,
F.
DEMARD
.
274
LONG-TERM
FOLLOW-UP
OF
THE
PATIENTS
WITH
RECURRENT
OR
ADVANCED
HEAD
AND
NECK
CANCER
WHO
RECEIVED
CHEMOTHERAPY
FOR
PALLIATION,
Y.
INUYAMA
.
280
INTENSIFIED
CONCOMITANT
CHEMORADIOTHERAPY
FOR
POOR
PROGNOSIS
HEAD
AND
NECK
CANCER,
E.E.
VOKES,
D.J.
HARAF,
W.
MORAN,
B.
WENIG,
D.
BRACH
MAN,
S.
RUBIN,
J.-M.
MCEVILLY,
P.
LUCKETT,
W.-R.
PANJE,
R.-R.
WEICHSELBAUM
.
283
CONTENTS
IX
RESPONSE
TO
CHEMOTHERAPY
OF
ULCERATIVE
LYMPHOMA
OF
THE
MIDFACE,
J.
CA
BANE,
CL.
GRANGE,
G.
LAMAS,
B.
MEYER,
P.
GODEAU,
J.-C.
IMBERT.
.
288
A
MULTICENTRIC
STUDY
OF
THE
GETTEC
(GROUPE
D
'
ETUDES
DES
TUMEURS
DE
LA
TETE
ET
DU
COU)
ABOUT
408
CLINICALLY
COMPLETE
RESPONDERS
AFTER
NEO
ADJUVANT
CHEMOTHERAPY
FOR
HEAD
AND
NECK
CARCINOMAS,
P.
CHAUVEL,
J.-L.
LEFEBVRE,
B.
LUBOINSKI,
G.
KANTOR,
M.
BOLLA,
G.
ANDRY,
J.
BRUGERE,
J.-J.
PESSEY,
F.
DEMARD
.
291
CHEMOTHERAPY
OF
UNDIFFERENTIATED
THYROID
CANCER
(UCT)
AND
SARCOMA
OF
THE
THYROID
GLAND
(ST),
F.
KOBER,
A.
HEISS,
B.
NEUGEBAUER,
R.
ROKA
295
RETINOID
CHEMOPREVENTION
OF
AERODIGESTIVE
CARCINOGENESIS,
W.-K.
HONG,
S.-M.
LIPPMAN,
S.-E.
BENNER,
J.-S.
LEE
.
298
DEFINITE
RADIATION
AND
CONCOMITANT
CISPLATIN
ADMINISTRATION
IN
LOCALLY
AD
VANCED
HEAD
AND
NECK
CANCER,
G.
FOUNTZILAS,
D.
SKARLOS,
P.
KOSMIDIS,
E.
SAMANTAS,
J.
TZITZIKAS,
P.
MAKRANTONAKIS,
P.
PANTELAKOS,
A.
NICOLAOU,
H.
BACOYIANNIS,
M.
SINODINOU,
P.
PAPASPYROU,
C.
BANIS,
A.
VRITSIOS,
J.
DANIILIDIS
.
303
IMPROVED
SURVIVAL
OF
PATIENTS
WITH
ADVANCED
SQUAMOUS
CELL
CARCINOMA
OF
THE
HEAD
AND
NECK
WITH
ALTERNATING
CHEMOTHERAPY
AND
RADIOTHERAPY,
M.
BENASSO,
R.
CORVO,
M.
CAVALLARI,
G.
SANGUINETI,
G.
MARGARINO,
R.
ROSSO,
V.
VITALE,
M.
MERLANO
AND
MEMBERS
OF
AFFILIATED
INSTITUTIONS
307
TREATMENT
OF
PATIENTS
WITH
CANCER
OF
THE
HEAD
AND
NECK
OR
ESOPHAGUS
WITH
CARBOPLATIN,
5-FU,
INTERFERON-A
AND
INTERLEUKIN-2,
O.
SCHLAPPACK,
A.
HAINZ,
P.
BERGHAMMER,
M.
GRASL,
M.
KAUTZKY,
G.
KMENT,
W.
DOBROWSKY,
C.
DITTRICH
.
311
SURGICAL
CONSIDERATIONS
IN
THE
TREATMENT
OF
WELL-DIFFERENTIATED
THYROID
CANCER,
I.
ROISMAN,
V.
BARAK,
D.
SAPIR,
A.
BITTERMAN,
N.
LIVNI,
J.
HONIGMAN,
Z.
GIMMON,
J.
MANNY,
A.L.
DURST
.
315
LUNG
CANCER
INTENSIVE
CHEMOTHERAPY
WITH
RECOMBINANT-HUMAN
GRANULOCYTE-MACROPHAGE
COLONY
STIMULATING
FACTOR
(R-HU-GM-CSF)
FOR
SMALL
CELL
LUNG
CANCER
(SCLC)
:
A
PILOT
STUDY,
C.
BESANA,
E.
BUCCI,
A.
BORRI,
G.
DI
LUCCA,
S.
TOGNELLA,
M.
TRESOLDI,
M.
MARCATTI,
C.
CORTI,
G.
CITTERIO,
F.
INVERSI,
C.
RUGARLI
319
SEQUENTIAL
HIGH-DOSE
CHEMOTHERAPY
WITH
R-METHU-G-CSF
(FILGRASTIM)
AND
INFUSION
OF
PERIPHERAL
BLOOD
PROGENITOR
CELLS
(PBPC)
IN
PATIENTS
WITH
SMALL
CELL
LUNG
CANCER
(SCLC).
A
FEASIBILITY
STUDY,
S.
LEYVRAZ,
N.
KETTERER,
J.PH.
GROB,
PH.
SCHNEIDER,
P.
VUICHARD,
V.
VON
FLIEDNER,
F.
LEJEUNE.
322
CISPLATINUM
AND
5-FLUOROURACIL
IN
SMALL
CELL
LUNG
CANCER,
J.F.
MORERE,
A.
DURAN,
F.
TCHERAKIAN,
C.
BOAZIZ,
J.P.
BATTESTI,
L.
ISRAEL,
J.L.
BREAU
328
PHASE
I-II
STUDY
OF
ORAL
ETOPOSIDE
AND
MODULATION
OF
DRUG
RESISTANCE
WITH
KETOCONAZOLE
IN
SMALL
CELL
LUNG
CANCER,
D.
DALLEY,
B.
BRIGHAM
.
331
ANGIOGENESIS
:
A
NOVEL
TARGET
FOR
ADJUVANT
CHEMOTHERAPY
IN
LOCALLY
AD
VANCED
NON-SMALL
CELL
LUNG
CANCER,
P.
MACCHIARINI,
G.
FONTANINI,
E.
DUL
X
CONTENTS
MET,
V.
DE
MONTPREVILLE,
A.
CHAPELIER,
B.
LENOT,
J.
CERRINA,
F.
LE
ROY
LADURIE,
P.
DARTEVELLE
.
336
A
STATISTICAL
MODEL
FOR
INVESTIGATING
ADJUVANT
CHEMOTHERAPY
IN
T1N0M0
NON-SMALL
CELL
LUNG
CANCER,
J.M.
HARDIN,
P.
MACCHIARINI,
K.P.
SINGH
343
A
COMBINATION
CHEMOTHERAPY
WITH
IFOSFAMIDE
(I),
CISPLATIN
(P)
AND
ETOPOSIDE
(E)
FOR
ADVANCED
NON-SMALL
CELL
LUNG
CANCER
(NSCLC),
G.
MAR
TIN,
M.J.
GARCIA,
J.J.
CRUZ,
A.
GDMEZ,
A.
PANADERO,
E.
FONSECA,
P.
SANCHEZ,
P.
SORIA,
J.
GARCIA,
J.C.
VALLEJO
.
348
MITOMYCIN,
IFOSFAMIDE
AND
PLATIN
(MIP)
IN
ADVANCED
AND
DISSEMINATED
NON-SMALL
CELL
LUNG
CANCER
(NSCLC),
P.J.
SOUQUET,
C.
BOHAS,
T.
ZENONE,
E.
MICHAUD,
M.T.
EL
KHOURY,
P.
ROMESTAING,
J.P.
BERNARD
.
351
PHASE
III
RANDOMIZED
STUDY
OF
NEO-ADJUVANT
CHEMOTHERAPY
SURGERY
IN
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
PRELIMINARY
RESULTS,
A.
DEPIERRE,
B.
MILLERON,
CL.
CHASTANG,
B.
LEBEAU,
P.
TERRIOUX,
E.
QUOIX,
D.
MORO,
G.
MIECH,
N.
PAILLOT,
J.L.
BRETON,
H.
DANICOT,
J.N.
LOMBARD,
J.
CLAVIER,
E.
LEMARIE,
P.
JACOULET
.
354
VINORELBINE,
5-FLUOROURACIL,
FOLINIC
ACID
AND
CISPLATIN
IN
NON-SMALL
CELL
LUNG
CANCER
:
VINDESINE
FOR
VINORELBINE
?
H.
DE
CREMOUX,
I.
MONNET,
N.
AZLI,
S.
VOISIN,
P.
RUFFIE,
L.
VERGNES,
J.
HUET,
J.C.
SALTIEL,
J.P.
AR
MAND,
E.
CVITKOVIC,
ATTIT
.
357
PREOPERATIVE
CHEMOTHERAPY
IN
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
-
A
PILOT
STUDY,
J.R.
FISCHER,
C.
MANEGOLD,
D.
BRANSCHEID,
I.
VOGT-MOYKOPF,
P.
DRINGS
.
362
NEO-ADJUVANT
CISPLATIN
AND
ETOPOSIDE
FOR
STAGE
IIIA
(CLINICAL
N2)
NON
SMALL
CELL
LUNG
CANCER,
S.
DARWISH,
V.
MINOTTI,
R.
ROSSETTI,
G.
CICCARESE,
L.
CRIND,
P.
FIASCHINI,
U.
MERCATI,
E.
MARANZANO,
P.
LATINI,
M.
TONATO
366
CONCOMITANT
CHEMORADIOTHERAPY
WITH
CISPLATIN
DOSE
ESCALATION
AS
PAL
LIATIVE
THERAPY
FOR
ADVANCED
MALIGNANCIES
OF
THE
CHEST,
C.
LEE
DRINKARD,
J.
DANIEL
HARAF,
C.
PHILIP
HOFFMAN,
M.
HARVEY
GOLOMB,
K.
MARK
FER
GUSON,
J.
NICHOLAS
VOGELZANG,
E.
EVERETT
VOKES
.
370
CONCOMITANT
CHEMORADIOTHERAPY
FOR
INOPERABLE
NON-SMALL
CELL
CARCINO
MA
OF
THE
LUNG
:
RESULTS
OF
CONTINUOUS
INFUSION
CISPLATIN
IN
85
PATIENTS,
F.
REBOUL,
P.
VINCENT,
B.
CHAUVET,
Y.
BREWER,
C.
FELIX
FAURE,
M.
TAULELLE
.
375
LATE
RESULTS
OF
NEO-ADJUVANT
CHEMORADIOTHERAPY
FOR
PRIMARY
INOPERA
BLE
NON-SMALL
CELL
LUNG
CANCER,
J.L.
REBISCHUNG,
J.M.
VANNETZEL,
P.
DARTEVELLE
.
377
GASTRO-INTESTINAL
TUMORS
CONSERVATIVE
TREATMENT
OF
ESOPHAGUS
CANCER
CONCOMITANT
CHEMORADIOTHER
APY
TREATMENT.
FIRST
RESULTS
OF
A
143
PATIENTS
SERIAL,
J.H.
JACOB,
A.
ROUS
SEL,
J.M.
OLLIVIER,
J.PH.
IZARD,
J.C.
VERNHES
.
383
INDUCTION
CHEMOTHERAPY,
SURGERY
AND
CONCOMITANT
CHEMORADIOTHERAPY
FOR
CONTENTS
XI
CARCINOMA
OF
THE
ESOPHAGUS,
P.C.
HOFFMAN,
M.K.
FERGUSON,
D.J.
HARAF,
L.C.
DRINKARD,
H.M.
GOLOMB,
E.E.
VOKES
.
386
SUPERIORITY
OF
COMBINED
CHEMORADIOTHERAPY
TO
RADIOTHERAPY
ALONE
IN
PA
TIENTS
WITH
ESOPHAGEAL
CANCERS.
AN
INTERGROUP
STUDY,
M.
AL-SARRAF,
K.
MARTZ,
A.
HERSKOVIC,
L.
LEICHMAN,
J.S.
BRINDLE,
V.K.
VAITKEVICIUS,
J.
COOPER,
R.
BYHARDT,
L.
DAVIS,
B.
EMAMI
.
389
NEO-ADJUVANT
CHEMORADIOTHERAPY
FOR
ADVANCED
GASTRIC
CANCER
:
A
PILOT
STUDY
WITH
ANGIOTENSIN
II
INDUCED
DRUG
DELIVERY
SYSTEM,
K.
SUGIYAMA,
H.
SATO,
M.
HOSHI,
M.
URUSHIYAMA,
K.
ISHIZUKA,
R.
KANAMARU
.
393
COMBINATION
OF
5-FU,
LEUCOVORIN
AND
CISPLATIN
(CDDP)
:
AN
EFFICIENT
LOW-TOXIC
CHEMOTHERAPY
IN
ADVANCED
GASTRIC
ADENOCARCINOMA,
M.
YCHOU,
Y.
FEDKOVIC,
A.
CHRISTOPOULOU,
B.
SAINT-AUBERT,
PH.
ROUANET,
C.
AS
TRE,
H.
PUJOL
.
396
ADJUVANT
CHEMOTHERAPY
AND
RADIOTHERAPY
IN
LIVER
TRANSPLANTATION
FOR
PRIMARY
HEPATOCELLULAR
CARCICOMA
:
A
FEASIBILITY
STUDY,
J.-Y.
PIERGA,
P.
PIED-BOIS,
D.
CHERQUI,
C.
DUVOUX,
A.
RAMOUNI,
J.-M.
METREAU,
D.
MATHIEU,
M.
JULIEN,
D.
DHUMEAUX,
P.-L.
FAGNIEZ,
J.-P.
LE
BOURGEOIS
399
INTENSIVE
WEEKLY
CHEMOTHERAPY
FOR
ADVANCED
GASTRIC
CANCER
USING
5-FLUOROURACIL,
CISPLATIN,
EPIRUBICIN,
6S-LEUCOVORIN
AND
GRANULOCYTE
COLONY
STIMULATING
FACTOR,
S.
CASCINU,
A.
FEDELI,
S.
LUZI
FEDELI,
G.
CATALANO
.
405
NEO-ADJUVANT
CHEMOTHERAPY
FOR
INOPERABLE
GASTRIC
CANCER
VIA
LOCAL
AND
GENERAL
DELIVERY
ROUTES
(FLEP
THERAPY),
T.
NAKAJIMA,
S.
ISHIHARA,
H.
MOTOHASHI,
Y.
KITAMURA,
Y.
NAKAJIMA,
M.
FUJII,
A.
TOKUNAGA,
K.
MATAI,
H.
ANZAI,
M.
NISHI
.
411
GASTRIC
CANCER
-
A
PLACE
FOR
PREOPERATIVE
INDUCTION
REGIONAL
CHEMOTHER
APY,
B.Y.
D.W.
STOREY,
P.J.
GALLAGHER,
R.C.
WAUGH,
F.O.
STEPHENS
414
A-2B-INTERFERON
(IFN)
PLUS
CHEMOTHERAPY
IN
INOPERABLE
BILIARY-TRACT
CAR
CINOMA,
PRELIMINARY
DATA,
G.
FRASCI,
M.
MONACO,
L.
CREMONE,
U.
SA
PIO,
F.
FAIELLA,
G.
PERSICO
.
419
A
PHASE
II
STUDY
OF
WEEKLY
48
HOURS
INFUSION
WITH
HIGH-DOSE
FLUOROURACIL
(FU)
IN
COLORECTAL
CANCER,
E.
ARANDA,
E.
DIAZ-RUBIO,
C.
CAMPS,
C.
FERNANDEZ-MARTO,
A.
CARRATO,
A.
ANTON,
A
CERVANTES,
J.J.
CRUZ
HERNANDEZ,
A.
TRES,
J.
BELON,
J.
SANCHEZ,
M.
GARCIA-PAREDES
.
422
PHASE
II
TRIAL
OF
FLUOROURACIL,
LEUCOVORIN
AND
INTERFERON-A,
R.M.
BUKOWSKI,
V.
GIBSON,
S.
MURTHY,
D.
MCLAIN,
T.
OLENCKI,
G.T.
BUDD
.
428
CONTINUOUS
SIMULTANEOUS
INTRA-ARTERIAL
AND
INTRAVENOUS
THERAPY
OF
LIVER
METASTASES
OF
COLORECTAL
CARCINOMA.
RESULTS
OF
A
PROSPECTIVE
RANDOMIZED
STUDY,
F.
SAFI,
K.H.
LINK,
H.G.
BEGER
.
433
D-VERAPAMIL
AND
ADRIAMYCIN
IN
THE
TREATMENT
OF
ADVANCED
COLORECTAL
CANCER,
W.
SCHEITHAUER,
G.
KORNEK,
S.
GLOBITZ,
M.
RADERER,
T.
SCHENK,
C.H.
MULLER,
C.H.
TETZNER
.
441
PERIOPERATIVE
MULTIMODAL
TREATMENT
OF
LOCALLY
ADVANCED
RECTAL
CANCER.
XII
CONTENTS
RESULTS
OF
A
PILOT
STUDY,
P.
SCHBFFSKI,
H.R.
RAAB,
I.
WILDFANG,
C.H.
KBHNE-WBMPNER,
J.H.
KARSTENS,
R.
PICHLMAYR,
H.J.
SCHMOLL
.
444
GYNECOLOGIC
CANCER
NEO-ADJUVANT
CHEMOTHERAPY
FOR
ADVANCED
OVARIAN
CANCER,
Y.
SHIMIZU,
S.
UMEZAWA,
N.
TAKESHIMA,
T.
KATO,
K.
HASUMI
.
453
HYPERFRACTIONATION
USING
WEEKLY
CISPLATIN,
CYCLOPHOSPHAMIDE
AND
ADRI
AMYCIN
(CAP)
IN
ADVANCED
EPITHELIAL
TUMORS
OF
THE
OVARY,
K.
TONKIN,
L.
LEVIN
.
460
ADJUVANT
TREATMENT
OF
OVARIAN
CARCINOMA,
I.B.
VERGOTE,
C.G.
TROPE,
L.N.
DE
VOS,
J.
KAERN,
W.M.
ABELER,
M.
WINDEREN,
E.O.
PETTERSEN
464
CYCLOPHOSPHAMIDE
(CTX)
AND
HIGH-DOSE
4-EPIDOXORUBICIN
(EPI)
IN
AD
VANCED
OVARIAN
CANCER
(OC)
TREATMENT,
G.
CARTEI,
M.
SIGNOR,
E.
VIGEVANI,
M.
GIOVANNONI,
A.
SIBAU,
G.
CLOCCHIATTI,
M.
MANSUTTI
.
469
HIGH-DOSE
CHEMOTHERAPY
(HDC)
AND
AUTOLOGOUS
BONE
MARROW
TRANSPLANT
(ABMT)
IN
39
ADVANCED
OVARIAN
CANCERS
:
LONG-TERM
RESULTS,
A.
LEGROS,
H.
CURE,
J.
FLEURY,
F.
SUZANNE,
J.
DAUPLAT,
PH.
CHOLLET,
R.
PLAGNE
473
CONCOMITANT
CHEMOTHERAPY
AND
RADIOTHERAPY
IN
THE
TREATMENT
OF
AD
VANCED
CERVIX
CARCINOMAS,
M.
RESBEUT,
M.
NOIRCLERC,
G.
GRAVIS,
CL.
D
'
ER
COLE,
P.
PECHIKOFF,
G.
HOUVENAEGHEL,
J.R.
DELPERO,
J.L.
BLACHE,
P.
VIENS
476
ADJUVANT
CHEMOTHERAPIES
FOR
SMALL
CELL
CARCINOMA
OF
THE
UTERINE
CERVIX,
T.C.
CHANG,
H.C.
CHANG,
C.H.
LAI,
S.
HSUEH,
S.F.
HUANG,
H.K.
CHANG,
Y.K.
SOONG
.
479
NEO-ADJUVANT
M-VAC
(METHOTREXATE,
VINBLASTINE,
DOXORUBICIN,
CISPLA
TIN)
CHEMOTHERAPY
FOR
LOCALLY
ADVANCED
OR
METASTATIC
CERVICAL
AND
VAGI
NAL
CANCER,
G.R.
GARTON,
T.O.
WILSON,
L.C.
HARTMANN,
H.J.
LONG,
K.C.
PODRATZ
.
482
A
PHASE
II
TRIAL
OF
NEO-ADJUVANT
CHEMOTHERAPY
(CT)
WITH
IFOSFAMIDE
(I),
MESNA
AND
CISPLATINUM
(C)
IN
STAGE
IIA-IIIB
CERVICAL
CANCER,
A.
ERA
ZO,
L.
TORRECILLAS,
G.
CERVANTES,
B.
ORTEGA
.
485
BLEOMYCIN,
IFOSFAMIDE
AND
CARBOPLATIN
IN
ADVANCED
UTERINE
CERVIX
CAR
CINOMA
:
PRELIMINARY
RESULTS,
C.
LOUVET,
S.
MOREAU,
A.
DE
GRAMONT,
C.
VARETTE,
B.
DEMUYNCK,
K.
BEERBLOCK,
L.
MARPEAU,
D.
ZYLBERAIT,
A.
PIGNE,
D.
SOUBRANE,
M.
KRULIK
.
488
UROLOGICAL
AND
GERMINAL
TUMORS
SURVEILLANCE
IN
STAGE
I
NON-SEMINOMATOUS
GERM
CELL
TUMORS
OF
THE
TESTIS
(NSGCTT).
EXPERIENCE
AT
THE
INSTITUTO
NACIONAL
DE
CANCEROLOGIA
OF
MEX
ICO,
J.W.
ZINSER,
R.
GAONA,
A.
MENDOZA,
O.
OCAMPO,
H.
DOMINGUEZ,
L.
VICENCIO
.
495
COMBINATION
CHEMOTHERAPY
WITH
ETOPOSIDE,
CISPLATIN,
BLEOMYCIN
AND
CY
CONTENTS
XIII
CIOPHOSPHAMIDE
FOR
ADVANCED
METASTATIC
NON-SEMINOMATOUS
GERM
CEIL
TUMORS,
A.
GERI,
C.
CLEMM,
M.
HENTRICH,
R.
HARTENSTEIN,
P.
KOHL,
W.
WILMANNS
.
499
EXTENTED
RESECTION
AFTER
PRIMARY
CHEMOTHERAPY
FOR
RESIDUAL
MALIGNANT
NON-SEMINOMATOUS
GERM
CELL
TUMORS
OF
THE
MEDIASTINUM
:
IS
IT
WORTH
WHILE
?
P.
MACCHIARINI,
E.
DULMET,
V.
DE
MONTPREVILLE,
A.
CHAPELIER,
B.
LENOT,
J.
CERRINA,
P.
DARTEVELLE
.
503
THE
PREDICTION
OF
TREATMENT
OUTCOMES
IN
NON-SEMINOMATOUS
EXTRAGONA
DAL
GERM
CELL
TUMORS
(NSEGCT)
BY
USING
DIFFERENT
CRITERIA
OF
POOR
AND
GOOD
RISK,
F.
GUTIERREZ
DELGADO,
A.
GARIN,
S.
TJULANDIN,
M.
RAMIREZ
MENDOZA,
A.
KHLEBNOV
.
510
ADVANCED
SEMINOMA
TREATED
WITH
CHEMOTHERAPY
(CT),
J.W.
ZINSER,
R.
GAONA,
A.
MENDOZA,
O.
OCAMPO,
H.
DOMINGUEZ-MALAGON,
E.
GO
MEZ,
L.
VICENCIO
.
513
CONCOMITANT
5-FU-CDDP
AND
BIFRACTIONED
SPLIT
COURSE
RADIATION
THERA
PY
FOR
INVASIVE
BLADDER
CANCER,
C.
MAULARD,
M.
HOUSSET,
Y.
CHRETIEN,
S.
DELANIAN,
F.
COLARDELLE,
J.P.
HALLEZ,
B.
DUFOUR,
F.
BAILLET
.
516
NEO-ADJUVANT
TREATMENT
FOR
LOCALLY
ADVANCED
BLADDER
CANCER
:
A
RAN
DOMIZED
PROSPECTIVE
CLINICAL
TRIAL,
A.
PELLEGRINI,
E.
CORTESI,
N.
GIOAC
CHINI,
E.
BALLATORI,
R.A.
VIRDIS
.
520
ULTRASTRUCTURAL
AND
CLINICAL
STUDY
OF
THE
UROTHELIUM
AFTER
INTERFERON-A-2B
TREATMENT,
P.
STRAVORAVDI,
J.
BELIVANIS,
TH.
DIMOPOULOS,
J.
HATZIGIAN
NIS,
M.
POLYZONIS
.
523
CHEMORADIOTHERAPY
IN
LOCALLY
ADVANCED
BLADDER
CANCER
:
NEO-ADJUVANT
AND
DEFINITIVE
TREATMENT,
L.
CANOBBIO,
F.
BOCCARDO,
A.
CUROTTO,
M.
PACE,
D.
GUARNERI,
A.
RUBAGOTTI,
M.
VENTURINI,
M.
ORSATTI,
V.
VI
TALE,
M.
SCHENONE,
M.
CUSSOTO,
C.
PEGORARO,
G.B.
TRAVERSO,
G.
SALVIA,
G.
MARTORANA,
L.
GIULIANI
.
527
INTERFERON-A
(IFN-A)
COMBINED
WITH
5-FIUOROURACIL
(5-FU)
IS
AN
ACTIVE
REGIMEN
IN
METASTATIC
RENAL
CELL
CANCER,
A.
SELLA,
L.
FINN,
R.
AMATO,
C.
LOGOTHETIS
.
535
COMPARATIVE
EFFICACY
OF
HORMONAL
THERAPY
USED
ALONE
OR
IN
COMBINA
TION
FOR
TREATMENT
OF
PROSTATIC
CARCINOMA,
W.
MULLOY
.
540
ETOPOSIDE
IN
TREATMENT
OF
HORMONE
REFRACTORY
ADVANCED
CARCINOMA
OF
THE
PROSTATE,
M.D.
FIROUZ
DANESHGARI,
E.
DAVID
CRAWFORD,
B.A.
SUZAN,
A.
MAJESKI
.
542
SEQUENTIAL
THERAPY
WITH
RECOMBINANT
INTERLEUKIN-2
(RIL-2)
AND
A-INTERFERON
(IFN)
FOR
ADVANCED
RENAL
CELL
CANCER
(RCC)
:
A
PRELIMINARY
REPORT,
C.
BE
SANA,
E.
BUCCI,
A.
BORRI,
A.
SCHOENHEIT,
G.
CITTERIO,
P.
MATTEUCCI,
S.
TOGNELLA,
C.
BAIOCCHI,
G.
LANDONIO,
E.
GHISLANDI,
C.
RUGARLI
.
548
NO
ADVANTAGE
FOR
THE
USE
OF
AN
EARLY
HIGH-DOSE
CHEMOTHERAPY
WITH
AU
TOLOGOUS
BONE
MARROW
TRANSPLANTATION
IN
FIRST-LINE
TREATMENT
OF
POOR
RISK
NON-SEMINOMATOUS
GERM
CELL
TUMORS,
H.
CURE,
J.P.
DROZ,
J.L.
PICO,
P.
BIRON,
P.
KERBRAT,
C.
CHEVREAU,
J.F.
HSRON,
B.
CHEVALLIER,
P.
FAR
XIV
CONTENTS
GEOT,
J.
BOUZY,
A.
KRAMAR,
AND
THE
UROLOGIC
GROUP
OF
THE
FRENCH
CANCER
CENTERS
FEDERATION
.
BONE
AND
SOFT
TISSUE
SARCOMAS
INITIAL
EXPERIENCE
WITH
AUTOLOGOUS
TRANSPLANTATION
OF
7
DAYS
NON
CRYOPRESERVED
PERIPHERAL
BLOOD
STEM
CELLS,
MOBILIZED
WITH
G-CSF,
IN
RHAB
DOMYOSARCOMA,
P.
SOBREVILLA-CALVO,
E.
REYNOSO-GOMEZ,
J.
DE
LA
GARZA
SALAZAR
.
HIGH-DOSE
CHEMOTHERAPY
WITH
GRANULOCYTE
COLONY-STIMULATING
FACTOR
IN
AD
VANCED
AND/OR
METASTATIC
SOFT
TISSUE
SARCOMAS,
S.
TOMA,
R.
PALUMBO,
U.
FOLCO,
G.
CANAVESE,
E.
AITINI,
E.
CANTONI,
M.
VINCENTI,
R.
ROSSO
TREATMENT
OF
OSTEOSARCOMA
WITH
CISPLATIN
AND
DOXORUBICIN
EITHER
AS
AD
JUVANT
OR
NEO-ADJUVANT
CHEMOTHERAPY,
J.W.
ZINSER,
N.
CASTANEDA,
A.
ALFEIRAN,
E.
MAAFS,
M.
DURAN,
G.
FLORES,
R.
GAONA,
L.
VICENCIO
THE
ROLE
OF
PREOPERATIVE
AND
ADJUVANT
CHEMOTHERAPY
IN
THE
TREATMENT
ON
NON
RHABDOMYOSARCOMA
SOFT
TISSUE
SARCOMA
IN
CHILDREN
AND
ADOLES
CENTS,
U.
GROSS-WIELTSCH,
M.
MORGAN,
E.
KOSCIELNIAK,
J.
TREUNER
.
ESCALATING
DOSES
OF
EPIRUBICIN
IN
COMBINATION
WITH
IFOSFAMIDE
AND
GM
CSF
IN
PREVIOUSLY
UNTREATED
SOFT
TISSUE
SARCOMA
PATIENTS
;
A
PHASE
I-II
STUDY,
S.
FRUSTACI,
A.
BUONADONNA,
D.
FAVARO,
M.
SANTAROSA,
F.
LATI
NI,
S.
LAMON,
E.
GALLIGIONI,
S.
MONFARDINI
.
PRIMARY
CHEMOTHERAPY
IN
MALIGNANT
FIBROUS
HISTIOCYTOMA
OF
BONE
-
UP
DATED
UTMD
ANDERSON
CANCER
CENTER
EXPERIENCE,
S.R.
PATEL,
T.
ARMEN,
C.H.
CARRASCO,
A.K.
RAYMOND,
A.G.
AYALA,
J.A.
MURRAY,
S.P.
CHAWLA,
R.S,
BENJAMIN
.
CONCOMITANT
RADIATION-DOXORUBICIN
ADMINISTRATION
IN
LOCALLY
ADVANCED
AND/OR
METASTATIC
SOFT
TISSUE
SARCOMAS,
S.
TOMA,
R.
PALUMBO,
A.
GRIMAL
DI,
S.
BARRA,
G.
CANAVESE,
B.
CASTAGNETO,
C.
FROLA,
E.
AITINI,
R.
ROSSO
MALIGNANT
MELANOMAS
AND
CEREBRAL
TUMORS
CHEMOTHERAPY
AS
A
FIRST
TREATMENT
FOR
MALIGNANT
PRIMARY
CNS
NON
HODGKIN
'
S
LYMPHOMA
OF
THE
CENTRAL
NERVOUS
SYSTEM
(PCNSL),
A.
BOIARDI,
A.
SILVANI,
A.
SALMAGGI,
S.
VALENTINI,
A.
ALLEGRANZA,
G.
BROGGI
.
EFFECT
OF
SIX
RETINOIDS
AND
RETINOIC
ACID
CATABOLIC
INHIBITOR
LIAROZOLE
ON
TWO
GLIOBLASTOMA
CELL
LINES,
AND
IN
VIVO
EXPERIENCE
IN
MALIGNANT
BRAIN
TUMOR
PATIENTS,
M.E.
WESTARP,
M.P.
WESTARP,
W.
BOLLAG,
J.
BRUYNSEELS,
H.
BIESALSKI,
N.
GROSSMANN,
H.H.
KORNHUBER
.
PHASE
II
TRIAL
WITH
BCNU
PLUS
A-2B-INTERFERON
IN
PATIENTS
WITH
RECUR
RENT
HIGH-GRADE
GLIOMAS,
A.
BRANDES,
P.
ZAMPIERI,
A.
RIGON,
E.
SCELZI,
P.L.
ZORAT,
A.
ROTILIO,
P.
AMISTA,
A.
PACCAGNELLA,
M.V.
FIORENTINO
CARBOPLATIN
COMBINED
WITH
CARMUSTINE
AND
ETOPOSIDE
IN
THE
TREATMENT
551
557
561
565
568
573
577
581
587
590
599
CONTENTS
XV
OF
GLIOBLASTOMA
(GBM)
PATIENTS,
A.
BOIARDI,
A.
SILVANI,
S.
VALENTINI,
A.
SALMAGGI,
M.
BOTTURI,
M.
FARINOTTI,
C.
GIORGI
.
604
PHASE
II
TRIAL
OF
CYSTEMUSTINE,
A
NEW
NITROSOUREA,
AS
SECOND-LINE
TREAT
MENT
OF
MALIGNANT
GLIOMAS,
A.
TISSERANT,
R.
PLAGNE,
H.
ROCHE,
A.
ADE
NIS,
P.
FARGEOT,
N.
GUIOCHET,
P.
CATTAN,
Y.
KRAKOWSKY,
M.A.
LENTZ,
P.
FUMOLEAU,
B.
CHEVALLIER,
P.
CHOLLET
.
607
AGE
EFFECT
ON
THE
SURVIVAL
OF
PATIENTS
WITH
GLIOBLASTOMA
AND
ANAPLASTIC
ASTROCYTOMA,
J.
HILDEBRAND,
THE
EORTC
BRAIN
TUMOUR
GROUP
.
612
CONCURRENT
RADIOCHEMOTHERAPY
IN
HIGH-GRADE
GLIOMA,
A.
BRANDES,
P.
ZAMPIERI,
A.
RIGON,
E.
SCELZI,
M.
PIGNATAROX,
F.
BERTI,
A.
ROTILIO,
A.
PADOAN,
P.
AMISTA,
A.
PACCAGNELLA,
M.V.
FIORENTINO
.
616
INTERFERON-A-2B
+
FOTEMUSTINE
IN
DISSEMINATED
MALIGNANT
MELANOMA,
L.
KOWALZICK,
P.
MOHR,
M.
WEICHENTHAL,
H.
LANGENBAHN,
D.K.
HOSS
FELD,
E.W.
BREITBART
.
620
TAMOXIFEN-AUGMENTED
BIOCHEMOTHERAPY
(INTERFERON-A-2B,
TAMOXIFEN,
BCNU,
CDDP,
DTIC)
FOR
MALIGNANT
MELANOMA,
H.
VOIGT,
R.
CLA/3EN,
J.
RAMAKER
.
623
LOCOREGIONAL
TREATMENT
CHEMOFILTRATION
FOR
LOCALLY
ADVANCED
CANCER,
M.
INBAR,
M.
GUTMAN,
S.
CHAITCHIK,
J.M.
KLAUSNER
.
631
TREATMENT
OPTIMIZATION
GUIDELINES
FOR
HYPERTHERMIC
ANTIBLASTIC
LIMB
PER
FUSION,
M.
PACE,
L.
MILLANTA,
A.
GALLI,
A.
BELLACCI
.
635
5-FU
+
FOLINIC
ACID
(FA,
RESCUVOLIN)
I.A.,
5-FU
+
FA
I.V.,
5-FUDR
I.A.,
OR
5-FUDR
I.A.
+
I.V.
FOR
TREATMENT
OF
NON-RESECTABLE
COLORECTAL
LIVER
MESTASTASES
?
K.H.
LINK,
E.D.
KREUSER,
F.
SAFI,
A.
SCHALHORN,
E.
SCHMOLL,
J.
PILLASCH,
H.G.
BEGER
.
639
HEPATIC
ARTERIAL
CHEMOTHERAPY
(HAI)
FOR
UNRESECTABLE
LIVER
METASTASES
FROM
GASTROINTESTINAL
CANCER,
F.
MUSCA,
R.
ESPOSITO,
G.
TOMA
.
649
THE
TREATMENT
OF
PRESACRAL
RECURRENCES
OF
RECTAL
CANCER
BY
THE
USE
OF
LOCO
REGIONAL
PELVIC
CHEMOTHERAPY.
A
DISCUSSION
OF
THESE
METHODS
AS
A
NEO
ADJUVANT
TIME
IN
LOCALLY
ADVANCED
RECTAL
TUMORS,
P.
MANIVIT,
R.
POLO,
D.
TABARY,
M.
NABET,
M.
POLO,
B.
RUBINI,
P.N.
CHIPPONI,
J.M.
FROMAGET,
M.
UNTEREINER
.
652
REPEATED
CHEMO-OCCLUSION
WITH
DEGRADABLE
STARCH
MICROSPHERES
(DSM)
-
ENHANCED
DRUG
UPTAKE
AND
REGIONAL
EFFICACY
IN
THE
TREATMENT
OF
PRIMARY
AND
SECONDARY
LIVER
TUMORS,
B.
NILSSON,
C.J.
JOHANSSON,
B.
BUNKE,
T.
TAGUCHI
.
658
ANTITUMOR
EFFICACY
OF
INTRAPERITONEAL
HYPERTHERMOCHEMOTHERAPY
COMBINED
WITH
AGGRESSIVE
SURGERY
FOR
PATIENTS
WITH
ADVANCED
GASTRIC
CANCER,
S.
FUJIMOTO,
M.
TAKAHASHI,
K.
KOBAYASHI,
T.
MUTOU,
M.
KURE,
H.
MASAOKA,
H.
OHKUBO
.
665
INTRAPERITONEAL
HYPERTHERMIC
CHEMOPERFUSION
IN
PATIENTS
WITH
PERITONEAL
XVI
CONTENTS
CARCINOMATOSIS
AND
MALIGNANT
ASCITES,
F.
KOBER,
B.
NEUGEBAUER,
A.
HEISS,
R.
ROKA
.
669
INTRA-AORTIC
INFUSION
CHEMOTHERAPY
IN
ADVANCED
PENILE
CARCINOMA,
M.C.
SHEEN,
H.M.
SHEU,
C.Y.
CHAI,
C.H.
HUANG,
Y.W.
WANG
.
672
PSYCHOSOCIAL
ISSUES
IN
CANCER
THE
INFLUENCE
OF
BOTH
SURGERY
AND
ADJUVANT
CHEMOTHERAPY
ON
BREAST
CANCER
WOMEN
QUALITY
OF
LIFE,
O.
CAFFO,
G.
AMBROSINI,
S.
AGUGIARO,
C.
ECCHER,
S.
MALUTA
.
677
PSYCHOLOGICAL
SIDE
EFFECTS
INDUCED
BY
INTERLEUKIN-2/A-INTERFERON
:
CLINI
CAL
OBSERVATIONS,
BIOLOGICAL
CORRELATIONS,
M.J.
SMITH,
R.
MOUAWAD,
E.
VUILLEMIN,
A.
BENHAMMOUDA,
C.
SOUBRANE,
D.
KHAYAT
.
681
QUALITY
OF
LIFE
IN
ADVANCED
COLORECTAL
CANCER,
G.
FRANCINI,
R.
PETRIOLI,
A.
AQUINO,
S.
MARSILI,
S.
BRUNI,
L.
LORENZINI,
S.
MANCINI,
M.
LORENZI,
G.
MARZOCCA,
F.
TANI,
S.
ARMENIO,
G.
TANZINI,
F.
CETTA,
F.
SILVETRINI,
C.
STACCI,
M.
NARDINI,
I.
D
'
ERRICO
.
691
ADVANCE
DIRECTIVES
IN
THE
INTENSIVE
CARE
UNIT
OF
A
TERTIARY
CANCER
CENTER,
M.S.
EWER,
J.
TAUBERT,
M.K.
ALI,
.
695
DO
CANCER
RELATED
PAIN
PROBLEMS
EXIST
IN
FRANCE
?
L.
BRASSEUR,
F.
LARUE,
M.
DUBIEZ,
S.
COLLEAU,
C.
CLEELAND
.
699
INTRAVENOUS
GRANISETRON-SIMPLE,
SAFE
AND
EFFECTIVE
SINGLE-DOSE.
ADMINIS
TRATION
FOR
CONTROL
OF
CHEMOTHERAPY
INDUCED
NAUSEA
AND
VOMITING,
S.G.
DILLY
.
702
CONTROL
OF
REFRACTORY
NAUSEA
AND
VOMITING
WITH
ADJUVANT
PROPOFOL
DUR
ING
CANCER
CHEMOTHERAPY,
A.
BORGEAT,
O.H.G.
WILDER-SMITH,
K.
RIFAT,
M.
FORNI
.
705
LIPOSOMAL
DAUNORUBICIN
TREATMENT
INCREASES
QUALITY
OF
LIFE
IN
HIV
ASSOCIATED
KAPOSI
'
S
SARCOMA,
C.A.
PRESANT,
M.
SCOLARO,
P.
KENNEDY,
D.W.
BLAYNEY,
B.
FLANAGAN,
J.
LISAK,
J.
PRESANT
.
707
BIOLOGY
AND
CLINICAL
PHARMACOLOGY
COMPARISON
OF
12
MULTIDRUG-RESISTANCE
MODULATING
AGENTS
IN
A
MODEL
OF
DOXORUBICIN-RESISTANT
RAT
GLIOBLASTOMA
CELLS
IN
VITRO,
J.
ROBERT,
S.
HUET,
S.
BENNIS,
C.
CHAPEY
.
713
DIFFERENTIAL
FORMATION,
REPAIR
AND
TOLERANCE
OF
CISPLATIN-INDUCED
DNA
DAMAGE
IN
TWO
HUMAN
SMALL
CELL
LUNG
CARCINOMA
CEIL
LINES,
B.T.
HILL,
S.A.
SHELLARD
.
720
IDENTIFICATION
OF
A
DISTINCTIVE
MULTIPLE
DRUG
RESISTANCE
PHENOTYPE
IN
TUMOUR
CELLS
FOLLOWING
IN
VITRO
EXPOSURE
TO
X-IRRADIATION,
B.T.
HILL,
R.H.D.
WHELAN,
S.
MCCLEAN
.
723
FUNCTIONAL
ACTIVITY
OF
P-GLYCOPROTEIN
LOCALIZED
IN
SUBCELLULAR
STRUCTURES
CONTENTS
XVII
AND
REVERSAL
OF
MULTIDRUG
RESISTANCE
(MDR),
G.
TOFFOLI,
L.
TUMIOTTO,
M.G.
DALL
'
ARCHE,
C.
CERNIGOI,
M.
BOIOCCHI
.
726
NEW
STRATEGY
FOR
THE
PRODUCTION
OF
MONOCLONAL
ANTIBODIES
TO
EXTERNAL
PORTION
OF
THE
P-GLYCOPROTEIN,
M.
PAGE,
X.
YANG,
P.
ROBY,
R.
PARADIS,
N.
BERKOVA
.
730
MYELOPEROXIDASE
IS
INVOLVED
IN
VINCRISTINE
RESISTANCE
IN
HUMAN
MYELOB
LASTIC
LEUKEMIA,
D.
SCHLAIFER,
M.R.
COOPER,
M.
ATTAL,
A.O.
SARTOR,
J.B.
TREPEL,
C.
MULLER,
G.
LAURENT,
C.E.
MYERS
.
736
A
NEW
MULTIDRUG
RESISTANCE
MODULATING
AGENT
S
9788
:
PRELIMINARY
REPORT
OF
THE
PHASE
CLINICAL
TRIAL
IN
COMBINATION
WITH
VINCRISTINE,
D.
KHAYAT,
A.
BENHAMMOUDA,
M.
WEIL,
E.
VUILLEMIN,
G.
BASTIAN,
E.
ANTOINE,
O.
RIXE,
G.
AUCLERC,
C.
LUCAS,
M.
SARKANY,
J.-P.
BIZZARI
.
740
EFFECT
OF
PENTOXIFYLLINE,
ETHACRYNIC
ACID
AND
O
6
-BENZYL-GUANINE
AS
RESISTANCE
MODIFIERS
TO
ALKYLATING
AGENTS
IN
HAEMATOLOGICAL
MALIGNANCIES,
M.R.
MULLER,
L.
SCHLENGER,
CHR.
BOOGEN,
M.R.
NOWROUSIAN,
S.
SEEBER
745
STRUCTURAL
ALTERATIONS
OF
HUMAN
TOPOISOMERASE
ILA
RESPONSIBLE
FOR
DRUG
RESISTANCE,
DNA-BINDING
AND
NUCLEAR
LOCALIZATION,
F.
BOEGE,
F.
GIESELER,
P.
MEYER
.
749
MEASUREMENT
OF
HUMAN
TUMOR
PHARMACOKINETICS
IN
VIVO
NONINVASIVELY
BY
19-F
MAGNETIC
RESONANCE
SPECTROSCOPY
PREDICTS
CLINICAL
5-FU
SENSITIVI
TY
AND
RESISTANCE,
C.A.
PRESANT,
W.
WOLF,
V.
WALUCH,
R.
BRECHNER,
C.
WISEMAN,
D.W.
BLAYNEY,
P.
KENNEDY
.
757
IMMUNOREGULATION
BY
TUMOR
NECROSIS
FACTOR
A
(TNF)
:
AN
OPPORTUNITY
FOR
THERAPEUTIC
INTERVENTION
?
E.
MIHICH,
D.
MACCUBBIN,
S.
POCCHIARI,
S.
UJHAZY,
S.
VERSTOVSEK,
M.J.
EHRKE
.
759
TUMOR
NECROSIS
FACTOR
ALPHA
:
ITS
RELATIONSHIP
WITH
CLINICAL
DATA,
J.J.
BOSCO
LOPEZ,
M.
ESCOBAR,
P.
GALLURT,
P.
RODRIGUEZ,
A.
LORENZO,
A.
MORAN,
A.
SENRA,
J.
MILLAN
.
765
THE
ANTIPROLIFERATIVE
EFFECT
OF
LYMPHOBLASTOID
A
INTERFERON
AND
ITS
ABILI
TY
TO
RE-INDUCE
OR
AMPLIFY
MAJOR
HISTOCOMPATIBILITY
COMPLEX
ANTIGEN
EX
PRESSION
ON
HUMAN
RENAL
CARCINOMA
CELLS
IN
CULTURE,
R.L.
ANGUS,
C.M.P.
COLLINS,
M.O.
SYMES
.
770
IS
THERE
ANY
PREDICTIVE
FACTOR
OF
THE
CLINICAL
RESPONSE
TO
IL-2
THERAPY
IN
METASTATIC
MALIGNANT
MELANOMA
?
CL.
SOUBRANE,
R.
MOUAWAD,
M.
ICHEN,
J.
SUISSA,
E.
VUILLEMIN,
CH.
BOREL,
A.
BENHAMMOUDA,
M.
WEIL,
D.
KHAYAT
774
HOW
IL-2
CAN
AFFECT
MELANOMA
CELLS,
S.
PLAISANCE,
A.
ALILECHE,
E.
RUBIN
STEIN,
D.
HAN,
B.
AZZARONE,
C.
JASMIN
.
779
POTENTIATION
OF
5-FLUOROURACIL-[6RS]LEUCOVORIN
CYTOTOXICITY
BY
RECOMBINANT
HUMAN
INTERFERON-A2A
IN
COLON
CARCINOMA
CELLS,
J.A.
HOUGHTON,
D.A.
AD
KINS,
P.J.
HOUGHTON
.
785
EVIDENCE
FOR
A
ROLE
OF
IMMUNOSUPPRESSION
IN
THE
PATHOGENESIS
OF
SMALL
CELL
LUNG
CANCER,
J.R.
FISCHER,
M.
SCHINDEL,
N.
STEIN,
H.
LAHM,
H.
GALLATI,
P.
DRINGS,
P.H.
KRAMMER
.
789
P53
EXPRESSION
IN
HUMAN
SOFT
TISSUE
SARCOMAS.
CORRELATION
WITH
BIOLOGICAL
XVIII
CONTENTS
AGGRESSIVENESS,
G.
TOFFOLI,
T.
PERIN,
C.
DOGLIONI,
S.
FRUSTACI,
A.
BUONADON
NA,
A.
DE
PAOLI,
C.
CERNIGOI,
L.
TUMIOTTO,
M.G.
DALL
'
ARCHE,
M.
BOIOCCHI
794
SYNERGISTIC
CYTOTOXICITY
AS
AN
ENDPOINT
FOR
THE
DEVELOPMENT
OF
RATIONAL
CHEMOTHERAPEUTIC.
DRUG
COMBINATIONS,
J.L.
ABBRUZZESE,
P.
FROST
.
798
5-FLUOROURACII
MAY
HAVE
DIFFERENT
MECHANISMS
OF
ACTION
DEPENDING
ON
THE
DOSE
SCHEDULE
:
CLINICAL
IMPLICATIONS,
C.
ASCHELE,
A.
SOBRERO,
A.
GUGLIEL
MI,
A.
MORI,
L.
TIXI,
E.
BOLLI,
R.
ROSSO,
J.R.
BERTINO
.
804
CLINICAL
STUDIES
OF
CPT-11
IN
JAPAN,
T.
TAGUCHI
.
809
EVALUATION
OF
CPT-11
AGAINST
HUMAN
XENOGRAFTS
OF
COLON
ADENOCARCINOMA
AND
CHILDHOOD
SARCOMAS,
P.J.
HOUGHTON,
J.A.
HOUGTHON
.
813
MICROENCAPSULATION,
TAMOXIFEN
ANALOGUES,
AND
IN
VIVO
MICROSCOPY
FOR
TUMOR
TARGETING,
D.
YANG,
S.
WALLACE,
L.-R.
KUANG,
C.
LI,
A.
CHERIF,
Z.
KAN,
P.
MCCUSKEY,
K.C.
WRIGHT
.
817
A
NEW
GENERATION
OF
DOXORUBICIN-LOADED
LIPOSOMES
WITH
IMPROVED
LOCALI
ZATION
IN
TUMORS
:
PRECLINICAL
AND
CLINICAL
STUDIES,
A.
GABIZON,
B.
UZIELY,
B.
KAUFMAN,
T.
SAFRA,
R.
CATANE,
Y.
BARENHOLZ
.
820
DEGRADABLE
STARCH
MICROSPHERES
INCREASE
THE
CYTOSTATIC
EFFECT
OF
THE
BIOREDUC
TIVE
DRUG
RSU-1069
(AZIRIDINE
2-NITROIMIDAZOLE)
AT
ARTERIAL
ADMINISTRATION
IN
RATS
WITH
A
LIVER
CARCINOMA,
U.
STENRAM,
G.
ROOS
.
823
THERAPEUTIC
USE
OF
POLYSPECIFIC
MAB-LABELLED
LIPOSOMES
AS
CARRIERS
FOR
RADI
OISOTOPES
AND
DRUGS,
G.
ROMBI,
F.
COSSU,
G.
MELIS,
V.
ANEDDA,
A.
FACCHINI
826
AN
IN
VITRO
MODEL
FOR
NEUTROPHIL-MEDIATED
DAMAGE
TO
TUMOUR
VASCULATURE
:
EFFECTS
OF
A
NOVEL
ANTI-CANCER
AGENT,
J.C.
MURRAY,
K.A.
SMITH,
M.
BASTAKI,
K.B.
WILSON
.
833
STIMULATION
OF
TUMOR
GROWTH
IN-VITRO
AND
IN-VIVO
BY
SURAMIN
IN
AN
EX
PERIMENTAL
MODEL,
M.
JULIERON,
L.
RAMIREZ,
M.
BONNAY,
G.
VASSAL,
A.
GAVOILLE,
D.
PIRON,
D.
GANDIA,
L.
MIR,
J.-N.
MUNCK
.
838
PHASE
I-II
TRIAL
OF
SERASPENIDE
(ACSDKP)
:
A
SUPRESSOR
OF
MYELOPOIESIS
PRO
TECTS
AGAINST
CHEMOTHERAPY
MYELOTOXICITY
(VERSION
10
FEBRUARY
1993),
P.
CARDE,
E.
GONCALVES,
F.
ISNARD,
E.
DESCHAMPS
DE
PAILLETTE,
C.
CHASTANG,
N.
MATHIEU-TUBIANA,
E.
VUILLEMIN,
V.
DELWAIL,
O.
CORBION,
A.
VEKHOFF,
J.-M.
FERRERO,
E.
GARCIA-GIRALT,
J.-F.
GIMONET,
A.M.
STOPPA,
E.
LEGER
PICHERIT,
J.-P.
MONPEZAT,
E.
FADEL,
C.
DOMENGE,
F.
GUILHOT,
F.
THOMAS,
D.
KHAYAT,
A.
MONNIER,
R.
ZITTOUN,
B.
BRUN,
D.
MARANINCHI,
J.-N.
MUNCK,
F.
BEAUJAN,
M.
GUIGON,
E.
FRINDEL,
A.
NAJMAN,
M.
TUBIANA
.
843
A
REVIEW
ON
THE
USE
OF
SHEEP
EPIDERMAL
SQUAMOUS
CELL
CARCINOMA
TO
EVALU
ATE
INTRA-ARTERIAL
INFUSION
CHEMOTHERAPY,
G.J.S.
HARKER,
F.O.
STEPHENS.
850
CELLULAR
AND
PHARMACOKINETIC
FACTORS
WHICH
INFLUENCE
GENOTOXICITY
OF
TOPOISOMERASE
II
INHIBITING
DRUGS
IN
HUMAN
LEUKEMIA
CELLS,
F.
GIESELER,
V.
NII/SLER
,
F.
BOEGE,
D.
BILLER,
P.
MEYER,
W.
WILLMANNS,
K.
WILMS
.
855
CLINICAL
APPLICATION
OF
GENE
TRANSFER
IN
ONCOLOGY
:
PRELIMINARY
RESULTS
OF
A
FRENCH
STUDY,
Y.
MERROUCHE,
C.
BAIN,
G.
CLAPISSON,
S.
NEGRIER,
B.
CORONEL,
A.
MERCATELLO,
J.-F.
MOSKOVTCHENKO,
B.
MOEN,
T.
PHILIP,
M.C.
FAVROT
861
CONTENTS
XIX
EFFECTS
OF
VITAMIN-A
ON
THE
OESTROGEN
DEPENDANT
BREAST
CARCINOMA
CELL
LINE
ZR75-1,
P.G.
HORGAN,
J.
O
'
DONOGHUE,
J.
BYRNE,
C.
PHELAN,
H.F.
GIVEN
865
MEASUREMENT
OF
THE
EARLY
LEVEL
OF
MDRL
GENE
EXPRESSION
IS
A
PREDICTIVE
MAR
KER
OF
TUMOUR
RESPONSE
IN
BREAST
CANCER
PATIENTS
TREATED
BY
NEO-ADJUVANT
CHEMOTHERAPY,
J.Y.
PIERGA,
S.
CHEVILLARD,
P.
POUILLART,
PH.
VIELH
.
871
HEMATOLOGIC
EFFECTS
OF
RECOMBINANT
HUMAN
INTERLEUKIN-6
(RHIL-6)
IN
SAR
COMA
PATIENTS
RECEIVING
MAID
CHEMOTHERAPY
:
PHASE
I
TRIAL,
R.M.
BUKOWSKI,
R.
ISAACS,
M.
GORDON,
G.D.
DEMETRI,
B.
AMUELS,
D.C.
YOUNG,
S.
SAMUEL,
D.
MCLAIN,
D.
LEVITT
.
875
ROLE
OF
G-CFS
AND
GM-CSF
IN
THE
TREATMENT
OF
FEBRILE
NEUTROPENIA
IN
DUCED
BY
CHEMOTHERAPY
;
PRELIMINARY
RESULTS
OF
A
RANDOMIZED
TRIAL,
F.
RIVERA,
J.I.
MAYORDOMO,
M.T.
DIAZ-PUENTE,
M.P.
LIANES,
M.
LOPEZ
BREA,
E.
LOPEZ,
L.
PAZ-ARES,
S.
ALONSO,
H.
CORTES-FUNES
.
880
FIRST
LINE
CHEMOTHERAPY
FOR
PATIENTS
WITH
MULTIPLE
MYELOMA
WITH
VAD
REGI
MEN
FOLLOWED
BY
CONSOLIDATION
WITH
HIGH-DOSE
CHEMORADIOTHERAPY
WITH
PERIPHERAL
STEM
CELLS
AUTOGRAFT
(PSCA)
:
THE
EXPERIENCE
OF
IGR
CENTER,
P.
BRAULT,
E.
GILLES,
A.
IBRAHIM,
F.
BEAUJEAN,
S.
JIMENZ,
G.
TERTIAN,
M.
HAYAT,
J.H.
BOURHIS,
J.L.
PICO
.
885
AUTHOR
'
S
INDEX
.
889 |
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV009261274 |
| classification_rvk | XH 3105 |
| ctrlnum | (OCoLC)31015396 (DE-599)BVBBV009261274 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV009261274</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19940519</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">940324s1994 ad|| |||| 10||| engod</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">940873346</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">2287003924</subfield><subfield code="9">2-287-00392-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540595996</subfield><subfield code="9">3-540-59599-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387595996</subfield><subfield code="9">0-387-59599-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)31015396</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009261274</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3105</subfield><subfield code="0">(DE-625)152887:12911</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer treatment</subfield><subfield code="b">an update</subfield><subfield code="c">ed. by : P. Banzet ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris u.a.</subfield><subfield code="b">Springer</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 901 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Combined Modality Therapy</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1993</subfield><subfield code="z">Paris</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Banzet, Pierre</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006162977&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006162977</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1993 Paris gnd-content |
| genre_facet | Konferenzschrift 1993 Paris |
| id | DE-604.BV009261274 |
| illustrated | Illustrated |
| indexdate | 2024-08-16T00:45:31Z |
| institution | BVB |
| isbn | 2287003924 3540595996 0387595996 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006162977 |
| oclc_num | 31015396 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM |
| physical | XIX, 901 S. Ill., graph. Darst. |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Springer |
| record_format | marc |
| spelling | Cancer treatment an update ed. by : P. Banzet ... Paris u.a. Springer 1994 XIX, 901 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Literaturangaben Combined Modality Therapy Congresses Neoplasms drug therapy Congresses Therapie (DE-588)4059798-2 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1993 Paris gnd-content Krebs Medizin (DE-588)4073781-0 s Therapie (DE-588)4059798-2 s DE-604 Banzet, Pierre Sonstige oth DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006162977&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Cancer treatment an update Combined Modality Therapy Congresses Neoplasms drug therapy Congresses Therapie (DE-588)4059798-2 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4059798-2 (DE-588)4073781-0 (DE-588)1071861417 |
| title | Cancer treatment an update |
| title_auth | Cancer treatment an update |
| title_exact_search | Cancer treatment an update |
| title_full | Cancer treatment an update ed. by : P. Banzet ... |
| title_fullStr | Cancer treatment an update ed. by : P. Banzet ... |
| title_full_unstemmed | Cancer treatment an update ed. by : P. Banzet ... |
| title_short | Cancer treatment |
| title_sort | cancer treatment an update |
| title_sub | an update |
| topic | Combined Modality Therapy Congresses Neoplasms drug therapy Congresses Therapie (DE-588)4059798-2 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Combined Modality Therapy Congresses Neoplasms drug therapy Congresses Therapie Krebs Medizin Konferenzschrift 1993 Paris |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006162977&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT banzetpierre cancertreatmentanupdate |